streptokinase + recombinant tissue plasminogen activator

The combination of streptokinase and recombinant tissue plasminogen activator (rtPA) refers to the thrombolytic regimen evaluated by Ain Shams University for the treatment of intermediate-high-risk pulmonary embolism (PE). Streptokinase is a non-enzymatic protein derived from beta-hemolytic streptococci that forms a complex with plasminogen, facilitating its conversion into active plasmin. Recombinant tissue plasminogen activator (rtPA), typically administered as alteplase, is a serine protease that directly cleaves plasminogen to plasmin, particularly in the presence of fibrin. These agents are used to rapidly dissolve obstructive thrombi in the pulmonary arteries, thereby reducing right ventricular strain and improving hemodynamic stability. In the specific clinical trial context (NCT04134104), these thrombolytics are investigated for their efficacy and safety in reducing 30-day mortality and bleeding events compared to standard anticoagulation with unfractionated heparin in patients with a low baseline risk of bleeding.

Brand names

StreptaseActivase

Other names

Thrombolytic therapyFibrinolytic therapyrtPAAlteplase